Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$0.45 USD
+0.03 (8.24%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $0.44 -0.01 (-1.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Applied Therapeutics Inc.'s return on equity, or ROE, is -354.24% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that APLT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
APLT 0.45 +0.03(8.24%)
Will APLT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
Company News for Dec 2, 2024
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Other News for APLT
Is APLT building bearish momentum? 180 Bearish Setup shows up after slipping 4.35%
Is APLT preparing to trend higher? Bullish Engulfing shows up after gaining 3.37%
APLT forms Lower Bollinger Band Walk on September 15
APLT falls 4.71% on September 12, leaving the technical picture intact
Is APLT primed for upward momentum? Stochastic Buy Signal shows up after slipping 0.7%